Depotech(depo) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo)

DEPO 7.300

+1.7%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: biao luo who wrote (568)	12/20/1997 12:31:00 AM
From: John McCarthy	Read Replies (3) of 887

<<The problem is FDA and the company evaluate the trial results differently. Especially the seven patients (61-53=8) left out when the company evaluated the data. Company's opinion: Depocyt treatment: 33% (8) of 24 responded Methotrexate: 17% (5) of 29 responded ODAC's opinion: Depocyt treatment: 8 of 31 (24 plus 7 who were not evaluable in company's opinion and who did not respond) Methotrexate 6 (5 plus 1 who was not evaluable according to the company and happened to be a responder) of 30 (29 plus 1)>> biao luo - Hi. I'm late on this and I apologize. The post - part of which I reference above - that you sent gave complete clarity to a totally confusing and ambiguous situation. I cannot thank you enough. So thanks! Andy, if your reading this, DITTO. I know you don't own any but it was sure nice having your thoughts on the situation. Regards, John McCarthy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next